Neurology · Muscle RelaxantSafety Signalregulatorynear-term

SyriMed recalls Baclofen oral solution due to crystallisation issues

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:33:36 AM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The recall of Baclofen oral solution due to crystallisation issues raises safety concerns that could influence prescriber and patient confidence. This situation presents an opportunity for competitors to gain market share if they can effectively address these concerns. Regulatory context from FDA (Fry Pie Factory Issues Voluntary Recall of Pepperoni Rolls for Undeclared Milk Allergen and Process Deviation) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this recall on sales and consider strategies to reassure prescribers and patients about product safety. The strongest clinical anchor is A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA) (ClinicalTrials.gov), sponsor/company relevance (roche). In Neurology · Muscle Relaxant, 6 regulatory and 2 competitive items passed relevance filtering for Baclofen.

Competitive Pressure

The most relevant competitive pressure comes from Abiomed Issues Correction for Automated Impella Controllers Due to Safety Concerns (Humanexa Signals) — moderate corpus alignment. Secondary pressure from Baxter's Volara System Faces Air Leak Issues Impacting Patient Therapy. This recall may impact market share for Baclofen products, particularly if competitors can capitalize on safety concerns.

Regulatory Outlook

Regulatory risk is concentrated around Fry Pie Factory Issues Voluntary Recall of Pepperoni Rolls for Undeclared Milk Allergen and Process Deviation (FDA). Mechanism alignment (IO ). Relevant agencies in corpus: FDA, MHRA. The recall may prompt increased scrutiny from regulatory agencies, potentially affecting future approvals or compliance requirements for similar products.

Key Risks

Elevated medium regulatory exposure for Baclofen could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (NARA ORGANICS RECALLS ALL LOTS OF NARA INFANT FORMULA BECAUSE OF POSSIBLE HEALTH RISK) could weigh on Baclofen through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

The recall may lead to a temporary decline in sales for Baclofen products, affecting revenue and market positioning, especially if competitors leverage the situation.
Portfolio teams should assess the impact of this recall on sales and consider strategies to reassure prescribers and patients about product safety.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall process and any potential regulatory actions or competitor responses.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Fry Pie Factory Issues Voluntary Recall of Pepperoni Rolls for Undeclared Milk Allergen and Process Deviation
FDAhigh relevance
Mechanism alignment (IO )
FDA document
View source
Western Mixers Produce & Nuts Issues Allergy Alert on Undeclared Peanuts in First Street Brand, Dark Chocolate Raisins
FDAhigh relevance
Mechanism alignment (IO )
FDA document
View source
NARA ORGANICS RECALLS ALL LOTS OF NARA INFANT FORMULA BECAUSE OF POSSIBLE HEALTH RISK
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Class 3 Medicines Recall: Orbit Pharma Limited, Cyclizine Lactate 50 mg/ml Solution for injection, EL(26)A/29
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
The Impact of Masseter Muscle Thickness on the Feeding Process in Preterm Infants in Ultrasound Assessment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of the Biological Function of Muscle Satellite Cells From Patients With Obstetric Brachial Plexus Palsy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Abiomed Issues Correction for Automated Impella Controllers Due to Safety Concerns
Humanexa Signalsmedium relevance
Moderate corpus alignment
Baxter's Volara System Faces Air Leak Issues Impacting Patient Therapy
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety and immunogenicity of a booster dose of COVAC-2, Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre tria
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Gallic acid-driven core-shell nanovehicles enable intestinal adhesion and adipose retention for enhanced oral bioavailability of cholecalciferol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Baclofen
competitors in the muscle relaxant market

Commercial impact

medium

The recall may lead to a temporary decline in sales for Baclofen products, affecting revenue and market positioning, especially if competitors leverage the situation.

Regulatory impact

medium

The recall may prompt increased scrutiny from regulatory agencies, potentially affecting future approvals or compliance requirements for similar products.

What to watch

Monitor for updates on the recall process and any potential regulatory actions or competitor responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.